Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.
Ruben A. Mesa, MD, director of the Mays Cancer Center at the University of Texas Health San Antonio MD Anderson Cancer Center, discusses emerging therapies in myelofibrosis.
Several emerging therapies in the pipeline are poised to have a significant impact on the myelofibrosis space, says Mesa.
For example, on April 3, 2020, the FDA approved luspatercept-aamt (Reblozyl) for the treatment of patients with myelodysplastic syndrome (MDS)-associated anemia. Notably, the agent could also enter the hemoglobinopathies paradigm.
Additionally, HDAC inhibitors, epigenetic modifiers, and checkpoint inhibitors are also under investigation in myelofibrosis, Mesa explains.
Furthermore, the field is hopeful that trials evaluating CALR-targeted vaccines will show favorable outcomes for patients with CALR-mutant disease, Mesa concludes.